Clinical Trial Record

Return to Clinical Trials

Nutrition in Gastrointestinal Tumors


2020-06-25


2022-12-06


2022-12-06


66

Study Overview

Nutrition in Gastrointestinal Tumors

Malnutrition and loss of muscle mass frequently occur in patients undergoing chemotherapy and can negatively effect therapy outcome. Especially patients with cancer of the gastrointestinal tract are often affected by malnutrition. Therefore, this study aims to examine changes in nutritional status of patients with cancer of the gastrointestinal tract during chemotherapy. Findings of this study will help to improve nutritional treatment of patients undergoing chemotherapy.

Malnutrition and sarcopenia are common complications in patients with malignant diseases of the gastrointestinal tract. During chemotherapy there is a high risk of further impairment of nutritional status due to anorexia, nausea, emesis and other gastrointestinal conditions that adversely impact food assimilation or absorption. Findings on changes of nutritional status during chemotherapy are scarce but of paramount importance for adequate nutrition therapy. Therefore, this study aims to provide a detailed description of changes in nutritional status of patients with a malignant condition of the gastrointestinal tract during chemotherapy.

  • Pancreatic Cancer
  • Oesophageal Cancer
  • Colon Cancer
  • Liver Cancer
  • Rectal Cancer
  • Bile Duct Cancer
  • GIST, Malignant
  • Neuroendocrine Tumors
  • Small Intestine Cancer
  • Gastric Cancer
  • OTHER: No intervention - observational study only
  • BB 071/20

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2020-06-29  

N/A  

2023-01-22  

2020-07-13  

N/A  

2023-01-25  

2020-07-17  

N/A  

2023-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Initial Diagnosis

Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.

OTHER: No intervention - observational study only

  • No intervention - observational study only
: Ongoing Cytostatic Treatment

Patients with a malignant condition of the gastrointestinal tract already receiving cytostatic treatment.

OTHER: No intervention - observational study only

  • No intervention - observational study only
Primary Outcome MeasuresMeasure DescriptionTime Frame
Prevalence of Malnutrition According to the Global Leadership Initiative on Malnutrition criteria (GLIM criteria)Change in prevalence of malnutrition according to the GLIM criteria3 months after study enrollment
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Prevalence of Malnutrition According to the European Society for Clinical Nutrition and Metabolism criteria (ESPEN criteria)Change in prevalence of malnutrition according to the ESPEN criteria3 months after study enrollment
Skeletal Muscle MassChanges in the skeletal muscle mass measured by Bioelectrical Impedance Analysis (BIA)3 months after study enrollment
Fat Free MassChanges in the fat free mass measured by Bioelectrical Impedance Analysis (BIA)3 months after study enrollment
Fat MassChanges in the fat mass measured by Bioelectrical Impedance Analysis (BIA)3 months after study enrollment
Total Body WaterChanges in the total Body water measured by Bioelectrical Impedance Analysis (BIA)3 months after study enrollment
Extracellular WaterChanges in the total extracellular water measured by Bioelectrical Impedance Analysis (BIA)3 months after study enrollment
Phase AngleChanges in the phase angle measured by Bioelectrical Impedance Analysis (BIA)3 months after study enrollment
Body WeightChanges in body weight measured in kilograms3 months after study enrollment
HeightChanges in height measured in meters3 months after study enrollment
Body Mass IndexChanges in body mass index in kg/m^2 (calculated from the values obtained for body weight and height)3 months after study enrollment
Waist CircumferenceChanges in waist circumference measured in centimeters3 months after study enrollment
Hip CircumferenceChanges in hip circumference measured in centimeters3 months after study enrollment
Waist-to-Hip RatioChanges in waist-to-hip ratio (calculated from the values obtained for waist and hip circumference)3 months after study enrollment
Upper Arm CircumferenceChanges in upper arm circumference measured in centimeters3 months after study enrollment
Triceps Skinfold ThicknessChanges in triceps skinfold thickness measured in millimeters3 months after study enrollment
Muscle StrengthChanges in muscle strength measured by a handgrip strength dynamometer3 months after study enrollment
Muscle FunctionChanges in muscle function measured by a 4-m gait speed test3 months after study enrollment
Sarcopenia According to the European Working Group on Sarcopenia in Older People 2 criteria (EWGSOP2 criteria)Change in prevalence of sarcopenia according to the EWGSOP2 criteria3 months after study enrollment
Energy IntakeChanges in energy intake assessed by 3-day weighed dietary record3 months after study enrollment
Protein IntakeChanges in protein intake (in g/day) assessed by 3-day weighed dietary record3 months after study enrollment
Carbohydrate IntakeChanges in carbohydrate intake (in g/day) assessed by 3-day weighed dietary record3 months after study enrollment
Fat IntakeChanges in fat intake (in g/day) assessed by 3-day weighed dietary record3 months after study enrollment
Dietary Fiber IntakeChanges in dietary fiber intake (in g/day) assessed by 3-day weighed dietary record3 months after study enrollment
Physical ActivityChanges in metabolic equivalent of task per day and activity level are assessed by employment of the German version of the International Physical Activity Questionnaire (IPAQ) Short Form3 months after study enrollment
Complete Blood CountChanges in complete blood count3 months after study enrollment
AlbuminChanges in plasma concentration of albumin3 months after study enrollment
Aspartate TransaminaseChanges in plasma concentration of aspartate transferase3 months after study enrollment
Alanine AminotransferaseChanges in plasma concentration of alanine aminotransferase3 months after study enrollment
Gamma-glutamyl TransferaseChanges in plasma concentration of gamma-glutamyl transferase3 months after study enrollment
BilirubinChanges in plasma concentration of bilirubin3 months after study enrollment
CreatinineChanges in plasma concentration of creatinine3 months after study enrollment
UreaChanges in plasma concentration of urea3 months after study enrollment
C-reactive ProteinChanges in plasma concentration of C-reactive protein3 months after study enrollment
Plasma MetabolomeChanges in plasma metabolome3 months after study enrollment
Plasma TranscriptomeChanges in plasma transcriptome3 months after study enrollment
Intestinal MicrobiomeChanges in intestinal microbiome3 months after study enrollment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.
  • ongoing cytostatic treatment of a known malignant condition of the gastrointestinal tract

  • Exclusion Criteria:

  • pregnancy
  • history of any other malignant tumor disease
  • inability to provide consent

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Ali A Aghdassi, Professor, University Medicine Greifswald

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available